A global phase 3 trial known as QWINT-1 demonstrated that the investigational basal insulin efsitora is as effective as daily glargine for managing blood glucose levels in insulin-naive adults with type 2 diabetes. Over 800 participants were involved, with HbA1c levels decreasing similarly in both groups after 52 weeks. Efsitora offered a lower incidence of severe hypoglycemia and required a lower average insulin dose, making it a promising once-weekly alternative to daily injections. Led by Dr. Julio Rosenstock, the results were presented at the ADA's 85th Scientific Sessions.
Weekly Efsitora Matches Glargine in HbA1c Control
Conexiant
July 8, 2025